Follow
Androgen Receptor
Androgen receptors are DNA-binding transcription factors activated by androgenic hormones. Genes regulated by these receptors are mainly responsible for the development of the male phenotype.
MAY 20, 2020 | 11:15 AM
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
OCT 10, 2019 | 1:30 PM
Metastatic castration resistant prostate cancer (mCRPC) refractory to secondary hormonal treatments such as enzalutamide or abiraterone acetate are the most lethal of prostate cancers. In thi...
DEC 05, 2017 | 6:00 AM
DATE: December 5th, 2017TIME: 6:00AM PTAndrogen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Nov...
AUG 30, 2017 | 10:00 AM
DATE: August 30, 2017TIME: 10:00am PT, 1:00pm ETRecent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers,...
OCT 06, 2016 | 6:00 AM
Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castr...
SEP 30, 2015 | 7:30 AM
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
OCT 17, 2013 | 10:00 AM
C.E. CREDITS
Prostate cancer epithelial cells depend on androgens for their survival. Because of this dependence, androgen deprivation therapy is the major treatment of advanced prostate cancer. Such ther...
OCT 16, 2013 | 1:00 PM
C.E. CREDITS
While androgen deprivation therapy (ADT) remains the primary treatment modality for patients with metastatic prostate cancer (PCa), treatment is uniformly marked by progression to castration-...